Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Hospira receives EC approval for new FN biosimilar

Hospira receives EC approval for new FN biosimilar

15th June 2010

Hospira has been granted approval by the European Commission (EC) to market Nivestim, its biosimilar treatment for preventing febrile neutropenia (FN), in EU member states.

The drug is the pharmaceutical company’s second biosimilar and is designed to deliver cost-reduction benefits in the treatment of FN, a serious haematological toxicity that occurs as a result of cancer chemotherapy.

It comes after the treatment was proven in a phase III clinical study to offer a similar level of efficacy to the branded product Neupogen.

Hospira states that its drug, which comes packaged in pre-filled syringes, can also be self-administered by patients, making it even more effective in terms of preserving healthcare resources.

Ron Squarer, chief commercial officer of Hospira, said: “Nivestim addresses unmet needs of patients and healthcare professionals through a unique combination of features that enhance convenience and safety, while reducing the cost of treatments.”

Earlier this year, Hospira expanded its presence in the generics market by completing a deal to purchase the generic injectable pharmaceuticals business of Indian company Orchid Chemicals and Pharmaceuticals.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.